Literature DB >> 15931032

Calcaneal lengthening for planovalgus foot deformity in children with spastic cerebral palsy.

Koji Noritake1, Yuji Yoshihashi, Toru Miyata.   

Abstract

The purpose of this study was to evaluate the effectiveness of calcaneal lengthening in the treatment of planovalgus foot deformity of children with spastic cerebral palsy. Sixteen children (27 feet) with spastic cerebral palsy underwent calcaneal lengthening along with peroneal tendons. The results were assessed clinically and radiographically. Over an average of 3.2 years of follow-up (2.0-5.0), 20 (74.1%) feet showed a satisfactory clinical result, and 21 (77.8%) feet showed a satisfactory radiographic result, according to the modified Mosca's criteria. Dependent ambulators with severe pes planovalgus showed unsatisfactory results compared with independent ambulators with mild to moderate pes planovalgus. These findings suggest that for severe pes planovalgus of children with cerebral palsy, it may be difficult to correct the foot deformity by calcaneal lengthening with peroneal tendons.

Entities:  

Mesh:

Year:  2005        PMID: 15931032     DOI: 10.1097/01202412-200507000-00008

Source DB:  PubMed          Journal:  J Pediatr Orthop B        ISSN: 1060-152X            Impact factor:   1.041


  12 in total

1.  Incidence and risk factors of allograft bone failure after calcaneal lengthening.

Authors:  In Hyeok Lee; Chin Youb Chung; Kyoung Min Lee; Soon-Sun Kwon; Sang Young Moon; Ki Jin Jung; Myung Ki Chung; Moon Seok Park
Journal:  Clin Orthop Relat Res       Date:  2014-11-14       Impact factor: 4.176

2.  [Extra-articular arthroereisis according to Grice/Green versus calcaneal lengthening according to Evans: retrospective comparison for therapy of neurogenic pes planovalgus].

Authors:  H Waizy; C Plaass; M Brandt; D Herold; C Stukenborg-Colsman; H Windhagen; L Claassen
Journal:  Orthopade       Date:  2013-06       Impact factor: 1.087

Review 3.  New clinical and research trends in lower extremity management for ambulatory children with cerebral palsy.

Authors:  Diane L Damiano; Katharine E Alter; Henry Chambers
Journal:  Phys Med Rehabil Clin N Am       Date:  2009-08       Impact factor: 1.784

4.  What are the long-term outcomes of lateral column lengthening for pes planovalgus in cerebral palsy?

Authors:  Karen M Kruger; Christopher S Constantino; Adam Graf; Ann Flanagan; Peter A Smith; Joseph J Krzak
Journal:  J Clin Orthop Trauma       Date:  2021-11-26

5.  Lateral column lengthening versus subtalar arthroereisis for paediatric flatfeet: a systematic review.

Authors:  Dong Hun Suh; Jung Ho Park; Soon Hyuck Lee; Hak Jun Kim; Young Hwan Park; Woo Young Jang; Jung Heum Baek; Hyun Jae Sung; Gi Won Choi
Journal:  Int Orthop       Date:  2019-01-30       Impact factor: 3.075

6.  Grice arthrodesis in the treatment of valgus feet in children with myelomeningocele: a 12.8-year follow-up study.

Authors:  Per Reidar Høiness; Eva Kirkhus
Journal:  J Child Orthop       Date:  2009-06-16       Impact factor: 1.548

7.  Calcaneal lengthening for planovalgus foot deformity in patients with cerebral palsy.

Authors:  Ki Hyuk Sung; Chin Youb Chung; Kyoung Min Lee; Seung Yeol Lee; Moon Seok Park
Journal:  Clin Orthop Relat Res       Date:  2012-11-21       Impact factor: 4.176

8.  Calcaneal lengthening osteotomy in spastic planovalgus feet.

Authors:  Amit Narang; Alok Sud; Dushyant Chouhan
Journal:  J Clin Orthop Trauma       Date:  2020-08-29

9.  Calcaneal lengthening for the pes planovalgus foot deformity in children with cerebral palsy.

Authors:  Aly Mohamed Aboelenein; Mohamed Lotfy Fahmy; Hassan Magdy Elbarbary; Abobakr Zein Mohamed; Sherif Galal
Journal:  J Clin Orthop Trauma       Date:  2018-07-29

10.  Concomitant calcaneo-cuboid-cuneiform osteotomies and the modified Kidner procedure for severe flatfoot associated with symptomatic accessory navicular in children and adolescents.

Authors:  Jung Ryul Kim; Chan Il Park; Young Jae Moon; Sung Il Wang; Keun Sang Kwon
Journal:  J Orthop Surg Res       Date:  2014-12-05       Impact factor: 2.359

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.